Gregg Gilbert
Stock Analyst at Truist Securities
(2.25)
# 2,750
Out of 5,148 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $19.65 | -13.49% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $41.60 | -11.06% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $62.34 | +34.74% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,017.97 | -48.43% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $4.29 | +203.03% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $13.52 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $121.41 | -23.40% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $24.76 | +93.86% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.65 | +1,475.76% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.62 | +24,152.22% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $12.34 | +532.09% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $128.96 | -39.52% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $33.77 | -46.70% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $202.55 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $190.46 | -8.12% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $234.26 | -71.83% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $19.65
Upside: -13.49%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $41.60
Upside: -11.06%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $62.34
Upside: +34.74%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,017.97
Upside: -48.43%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $4.29
Upside: +203.03%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $13.52
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $121.41
Upside: -23.40%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $24.76
Upside: +93.86%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.65
Upside: +1,475.76%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.62
Upside: +24,152.22%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $12.34
Upside: +532.09%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $128.96
Upside: -39.52%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $33.77
Upside: -46.70%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $202.55
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $190.46
Upside: -8.12%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $234.26
Upside: -71.83%